ALPHA COGNITION INC

Company Overview

Alpha Cognition Inc. is a clinical-stage biopharmaceutical company focused on treatments for neurodegenerative diseases, principally Alzheimer’s disease; its lead product ZUNVEYL (benzgalantamine) received FDA approval in July 2024 and launched in the U.S. on March 19, 2025 with a WAC of $749/month. The company is executing an LTC account‑based commercial strategy (32‑person U.S. salesforce) while retaining a small corporate headcount (52 FTEs) and outsourcing most development, manufacturing and clinical work to CROs/CMOs. The pipeline includes six preclinical programs and selective out‑licensing opportunities (including an exclusive Asia/Australia/NZ license), but material dependencies remain on third‑party CMC/CRO partners, payer coverage and reimbursement, and competition from generics and emerging disease‑modifying therapies. Management expects a multi‑year commercialization ramp and has indicated additional capital will likely be needed to scale U.S. sales and manufacturing.

Executive Compensation Practices

Filings show management has shifted spending from R&D to commercial and G&A as the company moved from development to launch, and share‑based compensation and consultant equity issuances were significant contributors to higher G&A. Given the company’s profile, compensation is likely tilted toward modest cash salaries with meaningful equity‑based incentives (options/RSUs, warrants or other liability‑based awards) and milestone/bonus arrangements tied to commercial metrics (prescription uptake, LTC account coverage, reimbursement wins) and licensing or milestone receipts. The use of convertible instruments and derivative/ warrant structures creates complex accounting for non‑cash compensation expense and can materially affect reported compensation charges in any period. In addition, retention awards and salesforce‑focused incentives are probable as Alpha Cognition scales distribution while conserving cash.

Insider Trading Considerations

Alpha Cognition’s filings disclose material convertible notes, warrants and share issuances tied to financing and consulting arrangements; those instruments and their marked‑to‑market volatility have driven large non‑cash losses and can create pressure for insider conversions or sales following financings. Insider trading activity should be monitored around clear liquidity and corporate events — follow‑on financings, convertible conversions, licensing milestone payments, quarterly sales disclosures and Medicare/reimbursement decisions — as these are likely to move the share price and trigger insider transactions. Regulatory constraints are meaningful: SEC Section 16 reporting, trading windows/blackouts, 10b5‑1 plans, and healthcare compliance rules (anti‑kickback/Open Payments) limit how commercial incentives are structured and how executives may trade around promotional and reimbursement information. For investors and traders, watch Forms 3/4/5 and any announced 10b5‑1 plans, and treat insider sales associated with financings or warrant exercises differently from sales that follow bona fide diversification or planned selling programs.